Phase 2 Epilepsy Trial, Recruiting (NCT05637086)

Phase 2 Epilepsy Trial, Recruiting NCT05637086 Sponsor: Mostafa Bahaa Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT05637086 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with grand mal epilepsy (a type of epilepsy involving full-body seizures) and are being treated with phenytoin as your only seizure medication
If you are a woman, you must either test negative for pregnancy before joining, or be using a reliable form of birth control

Who may not be able to join:

You have serious problems with your liver or kidneys
You currently use alcohol heavily or misuse drugs
You have a known allergy to any of the medications being used in this study
You have a known allergy to sulfonamide medications, as this may also cause a reaction to one of the study drugs (celecoxib)
You are pregnant or planning to become pregnant
You are taking any other medications that may have an effect on epilepsy or seizures
You are currently taking any other anti-seizure medications besides phenytoin
You have heart or cardiovascular disease, or you have previously had coronary artery bypass graft (heart bypass) surgery
You are currently taking aspirin or a medication called fluconazole (an antifungal medicine)
You have recently experienced bleeding in your eye (retina) or brain

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05637086

Sponsor: Mostafa Bahaa

Phase: Phase 2

Status: Recruiting

Condition: Epilepsy

More information: https://clinicaltrials.gov/study/NCT05637086

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with grand mal epilepsy (a type of epilepsy involving full-body seizures) and are being treated with phenytoin as your only seizure medication
If you are a woman, you must either test negative for pregnancy before joining, or be using a reliable form of birth control

Who may not be able to join:

You have serious problems with your liver or kidneys
You currently use alcohol heavily or misuse drugs
You have a known allergy to any of the medications being used in this study
You have a known allergy to sulfonamide medications, as this may also cause a reaction to one of the study drugs (celecoxib)
You are pregnant or planning to become pregnant
You are taking any other medications that may have an effect on epilepsy or seizures
You are currently taking any other anti-seizure medications besides phenytoin
You have heart or cardiovascular disease, or you have previously had coronary artery bypass graft (heart bypass) surgery
You are currently taking aspirin or a medication called fluconazole (an antifungal medicine)
You have recently experienced bleeding in your eye (retina) or brain

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Mostafa Bahaa

Registry

ClinicalTrials.gov

Start date

20 December 2022

Est. completion

20 December 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The clinical outcome will be assessed through Quality of Life questionnaire (QOLIE-31)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov